Propanc Biopharma (PPCB) Other Non-Current Liabilities (2013 - 2025)
Propanc Biopharma (PPCB) posted quarterly Other Non-Current Liabilities of $288635.0 for Q4 2025, up 119.35% year-over-year from $131585.0 in Q4 2024, and up 71.93% quarter-over-quarter from $167878.0 in Q3 2025.
Propanc Biopharma (PPCB) Other Non-Current Liabilities (2013 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Other Non-Current Liabilities for 13 consecutive years, with $288635.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities rose 119.35% year-over-year to $288635.0; the TTM figure through Dec 2025 stood at $288635.0 (up 119.35% YoY), while the FY2025 annual figure was $403892.0, up 201.67% from the prior year.
- Other Non-Current Liabilities improved to $288635.0 in Q4 2025 per PPCB's latest filing, from $167878.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $423209.0 in Q2 2023 and bottomed at $10623.0 in Q4 2022.
- Historically, Other Non-Current Liabilities has averaged $157655.0 across 5 years, with a median of $133193.5 in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities tumbled 95.21% — and 2023, when it soared 1961.99%.
- Propanc Biopharma's Other Non-Current Liabilities stood at $221977.0 in 2021, then sank by 95.21% to $10623.0 in 2022, then jumped by 1961.99% to $219045.0 in 2023, then plunged by 39.93% to $131585.0 in 2024, then soared by 119.35% to $288635.0 in 2025.
- Business Quant data shows PPCB's Other Non-Current Liabilities at $288635.0 in Q4 2025, $167878.0 in Q3 2025, and $403892.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 288,635.00 |
| Sep 30, 2025 | 167,878.00 |
| Jun 30, 2025 | 403,892.00 |
| Mar 31, 2025 | 191,770.00 |
| Dec 31, 2024 | 131,585.00 |
| Sep 30, 2024 | 134,234.00 |
| Jun 30, 2024 | 133,886.00 |
| Mar 31, 2024 | 128,432.00 |
| Dec 31, 2023 | 219,045.00 |
| Sep 30, 2023 | 119,069.00 |
| Jun 30, 2023 | 423,209.00 |
| Mar 31, 2023 | 132,501.00 |
| Dec 31, 2022 | 10,623.00 |
| Sep 30, 2022 | 72,958.00 |
| Jun 30, 2022 | 151,262.00 |
| Mar 31, 2022 | 56,612.00 |
| Dec 31, 2021 | 221,977.00 |
| Sep 30, 2021 | 58,124.00 |
| Jun 30, 2021 | 54,220.00 |
| Mar 31, 2021 | 53,189.00 |